Sorted By:


Brooke Ringel

PhRMA  |  Biography

Prior to joining PhRMA in June 2013, Brooke practiced international trade law at Kelley Drye & Warren LLP in Washington, specializing in export control and compliance.

Most 340B Hospitals Provide Little to Below Average Levels of Charity Care

Chartpack  |  From Our Network

Sixty-nine percent of 340B hospitals report charity care levels below the national average of 3.3%; 24% report levels below 1% of total costs.

Medicare Monday: There’s an agency called MedPAC?

PhRMA  |  Blog Post

And each March and June it releases reports to Congress on the commissioners’ final recommendations.

Many consumers still face confusion around health insurance coverage

PhRMA  |  Blog Post

  While progress has been made to make marketplace websites more consumer-friendly, these reports show improvements are necessary to ensure consumers have a clear understanding of the choices in front of them when picking a health plan.

2017 Research & Hope Awards honor innovators in mental health

PhRMA  |  Blog Post

The Medicines in Development report was released as part of PhRMA’s GOBOLDLY campaign in coordination with the newest chapter in the Together series featuring depression.

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

PhRMA  |  Blog Post

Adam Fein of Drug Channels recently reviewed the Magellan report.

Medicines have significantly increased chances of cancer survival around the globe

PhRMA  |  Blog Post

To learn more check out our International Cost in Context information.

Biopharmaceutical industry’s success reducing disparities for African Americans

PhRMA  |  Blog Post

We are excited about the 171 new medicines in development for type 1 and type 2 diabetes and related conditions such as chronic kidney disease, as well as the work many researchers are doing toward finding a cure.

PhRMA urges CMS to share the savings with seniors

PhRMA  |  Blog Post

The comments include new analysis from the actuarial firm Milliman which shows that rebate pass-through could alter market dynamics, strengthening plan incentives in the Part D program and reducing spending for beneficiaries and government alike: Over 10 years, shifting rebates to the point of sale could lower out-of-pocket costs for millions of Medicare beneficiaries, saving them between $4B and $28B The federal government could save between $8B and $73B over 10 years Part D has succeeded beyond expectations, delivering affordable prescription drug coverage for more than 40 million seniors and disabled individuals at a lower cost to taxpayers than was originally anticipated.

Higher deductibles and more dissatisfaction with health plans according to new poll

PhRMA  |  Blog Post

Those respondents are excluded from all reported survey results reported here except for the question about whether the respondent is in a high deductible plan.

ICYMI: What the experts are saying about importation

PhRMA  |  Blog Post

Bloomberg BNA reports that Tim Squire, a partner in the Toronto office of Fasken Martineau DuMoulin LLP and revered expert, said, “Canada's pricing controls don't apply to exports, so there is no guarantee Canadian products would be sold for the same prices in the United States…I don't think there are such huge savings to be had.”

New Analysis: Who Benefits from Contract Pharmacy Arrangements in 340B Program?

PhRMA  |  Blog Post

4] Alliance for Integrity and Reform of 340B, "Unfulfilled Expectations: An analysis of charity care provided by 340B hospitals," Spring 2014 (Available at:

Medicare Monday: How MedPAC recommendations would actually increase beneficiary costs

PhRMA  |  Blog Post

In April, the Medicare Payment Advisory Commission (MedPAC) voted on and approved a number of harmful Medicare Part D recommendations that were then presented to Congress in MedPAC’s June report.

Understanding the Drivers of Drug Expenditure in the U.S.

PhRMA  |  Report

The increasing list prices of specific medicines has been widely reported in a series of media events over the past two years, drawing the attention of the public, healthcare stakeholders, and politicians.

Research in New Jersey

PhRMA  |  Research In Your Backyard

This report shows how biopharmaceutical research companies continue to be vitally important to the economy and patient health in New Jersey.

New Analysis: 340B Program Shifting Delivery of Physician-Administered Medicines to More Expensive Hospital Settings

PhRMA  |  Press Release

“We encourage Congress and the Administration to reform the 340B program to help ensure it targets the patients and true safety-net facilities it was intended to help.”

The Next Five Years of PDUFA VI: Driving the availability of innovative treatments for patients

PhRMA  |  Blog Post

The FDA will also work with patient advocates, industry, and other stakeholders on patient-reported outcomes (PROs).

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Outdated rules in the following three key areas: government price reporting, Anti-Kickback Statute (AKS), and FDA rules on communications with payers, were reported by survey respondents as the greatest legal/regulatory barriers to advancing new approaches to paying for medicinesâ??

New PhRMA resources chock full of biopharma industry facts

PhRMA  |  Blog Post

  View the industry profile here and the chart pack here.

Chart Pack: Biopharmaceuticals in Perspective

PhRMA  |  Report

Data and information in this publication were drawn from a wide range of sources, including government agency reports, peer-reviewed journals, and the Pharmaceutical Research and Manufacturers of America’s (PhRMA’s) own research and analysis.

Scott LaGanga to Lead PhRMA State Advocacy; Shannon Graham to Lead Strategic Alliances

PhRMA  |  Press Release

“Scott has a proven track record of leading cross-disciplinary teams at the federal and state levels,” Ubl said.

Fact Check Friday: The truth about drug importation and patient safety

PhRMA  |  Blog Post

Robert Califf, former FDA Commissioner, stated that the “FDA would not be able to make safety and quality determinations for prescription drugs offered for import into the United States that have not gone through the U.S. regulatory process.”

Senior Director - Science and Regulatory Advocacy (Drug Development Tools)

PhRMA  |  PhRMA Career

Requirements  Bachelor’s degree in life sciences or related field; 5+ years of relevant experience in drug discovery and development, clinical trial design, patient reported outcomes, legal and regulatory frameworks or regulatory advocacy; Project management experience including the management of multiple projects simultaneously; Strong analytical and strategic planning skills; Excellent communication skills required:  verbal, written, listening and presentation; Ability to inspire confidence within the organization and with external constituencies.

Executive Assistant – Law Department

PhRMA  |  PhRMA Career

Professional Exerpience / Requirements High School Diploma required; some college education or bachelor’s degree preferred A minimum of 3+ years assisting a senior level executive preferably in a legal environment and in an environment requiring the handling of confidential information and documents Excellent communications skills, both verbal and written, including good editing skills Strong interpersonal skills, diplomacy and ability to work as a member of a team Excellent organizational skills with the ability to handle multiple tasks simultaneously Ability to work well under pressure Strong computer skills should include Microsoft Office (Word, Excel, PowerPoint, etc.) web, and database management Previous experience working with financial administrative tasks, such as financial reports and processing invoices Ability to work independently as well as lead and assist other support staff, while exercising good judgment  Ability to do some basic research; preferably have a basic understanding of legal research, processes and court filings  Who we are The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

SB 17 doesn’t address pressing prescription drug transparency issues for CA voters

PhRMA  |  Blog Post

Rather, it calls for mounds of red tape and government reports that look only at the list price of a prescription drug rather than considering actual patient spending after negotiated discounts and rebates.

You have reviewed the first 325 results out of 1032. Each page contains 25 results. You're on page 13.

prev 13 14 15 16 17 18 next